INOVIO PHARMACEUTICALS Business Summary

INOVIO Pharmaceuticals, Inc. (INO) is a clinical-stage biotechnology company specializing in the development of synthetic DNA medicines and proprietary electroporation delivery systems. The company primarily generates revenue through government grants, research contracts, and strategic licensing agreements, though it remains largely pre-commercial with a trailing twelve-month revenue of approximately $182,000 as of late 2025. Its business is segmented into its DNA medicines platform, which utilizes optimized DNA plasmids to trigger immune responses, and its CELLECTRA® smart-device technology designed for precise intradermal or intramuscular delivery. INOVIO is currently focused on the commercialization of its lead candidate, INO-3107, for the treatment of Recurrent Respiratory Papillomatosis (RRP), which has an FDA PDUFA action date set for October 30, 2026. In the competitive landscape, INOVIO contends with major players like Moderna, BioMarin Pharmaceutical, and Vertex Pharmaceuticals, as well as direct RRP competitor Precigen; it distinguishes itself by utilizing a non-viral, DNA-based approach that avoids the anti-vector responses and cold-chain requirements often associated with mRNA and viral-vector platforms. Leadership is spearheaded by President and CEO Dr. Jacqueline Shea, a molecular biologist with over 25 years of experience who previously served as CEO of Aeras and held executive roles at Emergent BioSolutions. The executive team includes CFO Peter Kies, who has managed the company’s financial strategy since 2002, and Chief Medical Officer Dr. Michael Sumner. INOVIO was co-founded by Dr. J. Joseph Kim, a former Merck vaccine developer, and Dr. David B. Weiner, widely regarded as the "father of DNA vaccines" and a professor at the Wistar Institute. The company’s Board of Directors features high-pedigree industry veterans, including Chairman Simon X. Benito (former Senior VP at Merck) and Dr. Roger D. Dansey (Chief Medical Officer at Seagen). Notable institutional backing includes significant positions held by The Vanguard Group, BlackRock, and Adage Capital Partners, reflecting continued investor interest in the scalability of the company’s DNA-encoded monoclonal antibody (DMAb) technology.